FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362540957> ?p ?o ?g. }

• W4362540957 endingPage "1830" @default.
• W4362540957 startingPage "1830" @default.
• W4362540957 abstract "Abstract Introduction: Combination anti-CTLA-4 antibody (Ab) + anti-PD-1 Ab is approved in multiple cancer types and has improved clinical outcomes. In addition, atezolizumab + bevacizumab combination therapy is approved for unresectable hepatocellular carcinoma. Given the rapid changes in the therapeutic landscape, it is important to investigate effective treatments for people with prior ICI-based combination therapy. E7386 modulates Wnt/β-catenin signaling, and a phase 1 study in combination with LEN (a receptor tyrosine kinase inhibitor that mainly targets both VEGFR and FGFR), in people with solid tumors (NCT04008797) is ongoing. In this study, we examined the antitumor activity of the combination of E7386 + LEN, with either prior anti-CTLA-4 Ab + anti-PD-1 Ab or anti-PD-1 Ab + aflibercept (a soluble decoy receptor against VEGF), in the mouse lung tumor KLN 205 model. Methods: Antitumor activity of E7386 (25 or 50 mg/kg), LEN (3 mg/kg), and the combination, was evaluated in the KLN 205 model (orally, once daily x 14 days), with or without prior treatments of either anti-CTLA-4 Ab (0.2 mg/head, weekly x 3, intraperitoneally [ip]) + anti-PD-1 Ab (0.2 mg/head, weekly x 3, ip)─ie, CTLA-4 + PD-1; or aflibercept (5 mg/kg) + anti-PD-1 Ab (0.2 mg/head, twice a week x 2, ip)─ie, AFL + PD-1. Mice with relatively rapid-growing tumors and prior treatments were given E7386, LEN, and their combination. RNA-seq analyses were conducted by using tumor tissues collected from mice one day after the prior treatment period or without treatment to analyze gene-expression alterations with prior treatments. Results: In the mouse model without prior treatments, LEN had clear antitumor activity. E7386 had limited antitumor activity as a monotreatment. E7386 + LEN had superior antitumor activity vs LEN in a dose-dependent manner. In addition, E7386 + LEN had superior antitumor activity to each single treatment despite either prior CTLA-4 + PD-1 or AFL + PD-1. E7386 + LEN with prior CTLA-4 + PD-1 had equivalent antitumor activity to LEN without prior treatments. Conversely, E7386 + LEN with prior AFL + PD-1 had strong antitumor activity, including marked tumor regression, compared to both LEN alone and E7386 + LEN without prior treatments. RNA-seq analyses showed that intratumoral Axin2, a target gene in the canonical Wnt-signaling pathway, was upregulated with prior AFL + PD-1—suggesting a potential activation of the Wnt-signaling pathway. Conclusion: E7386 + LEN combination shows antitumor activity in the mouse KLN 205 lung tumor model when there is prior ICI-based (CTLA-4 + PD-1 or AFL + PD-1) combination treatment. Further, E7386 + LEN shows enhanced antitumor activity with prior AFL + PD-1; possibly due to activation of Wnt-signaling pathway during prior treatments. Citation Format: Satoshi Kawano, Yusuke Adachi, Megumi Kuronishi, Kohta Toshimitsu, Kotaro Kodama, Takayuki Kimura, Masahiko Kume, Jialing Shen, Saori Watanabe Miyano, Akira Yokoi, Junji Matsui, Yu Kato, Yasuhiro Funahashi. E7386, a selective inhibitor of the interaction between β-catenin and CREB-binding protein (CBP), in combination with lenvatinib (LEN), exerts antitumor activity in preclinical tumor models with prior immune checkpoint inhibitor (ICI)-based combination treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1830." @default.
• W4362540957 created "2023-04-06" @default.
• W4362540957 creator A5000369615 @default.
• W4362540957 creator A5003415756 @default.
• W4362540957 creator A5006210040 @default.
• W4362540957 creator A5019271725 @default.
• W4362540957 creator A5024829665 @default.
• W4362540957 creator A5026904461 @default.
• W4362540957 creator A5037399627 @default.
• W4362540957 creator A5039847095 @default.
• W4362540957 creator A5044623118 @default.
• W4362540957 creator A5060408005 @default.
• W4362540957 creator A5065995617 @default.
• W4362540957 creator A5079407472 @default.
• W4362540957 creator A5081072346 @default.
• W4362540957 date "2023-04-04" @default.
• W4362540957 modified "2023-10-18" @default.
• W4362540957 title "Abstract 1830: E7386, a selective inhibitor of the interaction between β-catenin and CREB-binding protein (CBP), in combination with lenvatinib (LEN), exerts antitumor activity in preclinical tumor models with prior immune checkpoint inhibitor (ICI)-based combination treatment" @default.
• W4362540957 doi "https://doi.org/10.1158/1538-7445.am2023-1830" @default.
• W4362540957 hasPublicationYear "2023" @default.
• W4362540957 type Work @default.
• W4362540957 citedByCount "0" @default.
• W4362540957 crossrefType "journal-article" @default.
• W4362540957 hasAuthorship W4362540957A5000369615 @default.
• W4362540957 hasAuthorship W4362540957A5003415756 @default.
• W4362540957 hasAuthorship W4362540957A5006210040 @default.
• W4362540957 hasAuthorship W4362540957A5019271725 @default.
• W4362540957 hasAuthorship W4362540957A5024829665 @default.
• W4362540957 hasAuthorship W4362540957A5026904461 @default.
• W4362540957 hasAuthorship W4362540957A5037399627 @default.
• W4362540957 hasAuthorship W4362540957A5039847095 @default.
• W4362540957 hasAuthorship W4362540957A5044623118 @default.
• W4362540957 hasAuthorship W4362540957A5060408005 @default.
• W4362540957 hasAuthorship W4362540957A5065995617 @default.
• W4362540957 hasAuthorship W4362540957A5079407472 @default.
• W4362540957 hasAuthorship W4362540957A5081072346 @default.
• W4362540957 hasConcept C121608353 @default.
• W4362540957 hasConcept C126322002 @default.
• W4362540957 hasConcept C2775949291 @default.
• W4362540957 hasConcept C2776264508 @default.
• W4362540957 hasConcept C2776694085 @default.
• W4362540957 hasConcept C2776999253 @default.
• W4362540957 hasConcept C2777701055 @default.
• W4362540957 hasConcept C2777802072 @default.
• W4362540957 hasConcept C2778019345 @default.
• W4362540957 hasConcept C2778695046 @default.
• W4362540957 hasConcept C2778749236 @default.
• W4362540957 hasConcept C2780057760 @default.
• W4362540957 hasConcept C502942594 @default.
• W4362540957 hasConcept C71924100 @default.
• W4362540957 hasConcept C98274493 @default.
• W4362540957 hasConceptScore W4362540957C121608353 @default.
• W4362540957 hasConceptScore W4362540957C126322002 @default.
• W4362540957 hasConceptScore W4362540957C2775949291 @default.
• W4362540957 hasConceptScore W4362540957C2776264508 @default.
• W4362540957 hasConceptScore W4362540957C2776694085 @default.
• W4362540957 hasConceptScore W4362540957C2776999253 @default.
• W4362540957 hasConceptScore W4362540957C2777701055 @default.
• W4362540957 hasConceptScore W4362540957C2777802072 @default.
• W4362540957 hasConceptScore W4362540957C2778019345 @default.
• W4362540957 hasConceptScore W4362540957C2778695046 @default.
• W4362540957 hasConceptScore W4362540957C2778749236 @default.
• W4362540957 hasConceptScore W4362540957C2780057760 @default.
• W4362540957 hasConceptScore W4362540957C502942594 @default.
• W4362540957 hasConceptScore W4362540957C71924100 @default.
• W4362540957 hasConceptScore W4362540957C98274493 @default.
• W4362540957 hasIssue "7_Supplement" @default.
• W4362540957 hasLocation W43625409571 @default.
• W4362540957 hasOpenAccess W4362540957 @default.
• W4362540957 hasPrimaryLocation W43625409571 @default.
• W4362540957 hasRelatedWork W3048473883 @default.
• W4362540957 hasRelatedWork W3086685948 @default.
• W4362540957 hasRelatedWork W3092988017 @default.
• W4362540957 hasRelatedWork W3121710876 @default.
• W4362540957 hasRelatedWork W4226253563 @default.
• W4362540957 hasRelatedWork W4283217649 @default.
• W4362540957 hasRelatedWork W4310755779 @default.
• W4362540957 hasRelatedWork W4361803263 @default.
• W4362540957 hasRelatedWork W4378982512 @default.
• W4362540957 hasRelatedWork W4206883438 @default.
• W4362540957 hasVolume "83" @default.
• W4362540957 isParatext "false" @default.
• W4362540957 isRetracted "false" @default.
• W4362540957 workType "article" @default.